Roman Kniazev

Roman Kniazev is a seasoned professional with over 15 years of experience in the biotechnology industry. From investments to board positions, Roman has played a significant role in shaping the industry over the years. He brings a unique combination of financial and scientific expertise to his current role as CEO of a California-based biotech startup that develops vaccines for brain-related diseases.

​

Roman started his career as an investment professional, working for a major $5 billion European venture fund as an Investment Director. In his role, he was responsible for identifying, evaluating, and investing in promising biotech companies. During their time at the venture fund, Roman played a crucial role in several successful investments, helping to drive the growth of several innovative biotech companies.

In addition to their work as an investment professional, Roman has also served on the board of directors for several biotech companies, including several public companies. He has brought his expertise and industry insights to these roles, helping to guide these companies toward success.

​

In their current role as CEO of a California-based biotech startup Nuravax, Roman is putting his expertise and experience to use in the development of vaccines for brain-related diseases. Nuravax is in phase 1 clinical stage now, but Roman is confident that their vaccine candidates have the potential to make a significant impact in the fight against these diseases.

​

Roman holds a degree in economics and is currently pursuing a degree in general biotech science at UCLA. He is passionate about staying at the forefront of the industry and continuously expanding his knowledge and skills. This ongoing education, combined with Roman's extensive experience, positions them well to lead his biotech startup toward success. 

A member of Class 17.